FDA Gives Nod To Eli Lilly's First Treatment For Type Of Inflammatory Bowel Disease, To Compete With JNJ, Pfizer, AbbVie
Portfolio Pulse from Vandana Singh
The FDA has approved Eli Lilly's Omvoh (mirikizumab-mrkz) for moderately to severely active ulcerative colitis in adults. This marks Lilly's first approved treatment for a type of inflammatory bowel disease. The approval will allow Lilly to compete in a sector where drugs from AbbVie, Pfizer, and Johnson & Johnson are already present. Omvoh is expected to be available in the US in the coming weeks.
October 27, 2023 | 2:28 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
AbbVie may face increased competition in the inflammatory bowel disease treatment market due to Eli Lilly's new FDA approval.
The FDA approval of Eli Lilly's Omvoh could increase competition in the inflammatory bowel disease treatment market, potentially affecting AbbVie's market share and revenues.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 60
NEGATIVE IMPACT
Johnson & Johnson may face increased competition in the inflammatory bowel disease treatment market due to Eli Lilly's new FDA approval.
The FDA approval of Eli Lilly's Omvoh could increase competition in the inflammatory bowel disease treatment market, potentially affecting Johnson & Johnson's market share and revenues.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 60
NEGATIVE IMPACT
Pfizer may face increased competition in the inflammatory bowel disease treatment market due to Eli Lilly's new FDA approval.
The FDA approval of Eli Lilly's Omvoh could increase competition in the inflammatory bowel disease treatment market, potentially affecting Pfizer's market share and revenues.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 60
POSITIVE IMPACT
Eli Lilly's new FDA approval for Omvoh could boost its presence in the inflammatory bowel disease treatment market.
The FDA approval of Omvoh marks Eli Lilly's entry into the inflammatory bowel disease treatment market, which could potentially increase its revenues and market share.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100